SCM
PVLA

Silverarc Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Silverarc Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,017
Closed -$159K – 100
2023
Q2 		$159K Buy
+12,017
New +$729K 0.05% 77
2021
Q2 		– Sell
-625
Closed -$129K – 117
2021
Q1 		$129K Buy
+625
New +$137K 0.07% 88

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Silverarc Capital Management's PVLA Position: Q3 2023 in Review

Silverarc Capital Management sold out of Palvella Therapeutics (PVLA) in Q3 2023, closing a stake of 12,017 shares — an estimated $159K sold.

Silverarc Capital Management first reported a position in PVLA in Q1 2021 and held it in 2 quarters. The position peaked at $159K in Q2 2023. 43 funds tracked by Wall St. Rank hold PVLA as of Q3 2023.

  • Silverarc Capital Management reported no remaining Palvella Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 12,017 Palvella Therapeutics shares in Q3 2023, an estimated $159K.
  • Silverarc Capital Management first reported a position in Palvella Therapeutics in Q1 2021 and held it in 2 quarters.
  • Silverarc Capital Management's Palvella Therapeutics position peaked at $159K in Q2 2023.
  • 43 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2023.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.